Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population Meeting Abstract
| Authors: | Garon, E. G.; Rizvi, N. A.; LeighI, N. B.; Hui, R.; Eder, J. P.; Patnaik, A.; Aggarwal, C.; Horn, L.; Balmanoukian, A. S.; Gubens, M. A.; Felip-Font, E.; Costa, E. C.; Soria, J. C.; Ahn, M. J.; Arkenau, H. T.; Lee, J. S.; Robinet, G.; Lubiniecki, G. M.; Zhang, J.; Emancipator, K.; Rutledge, R.; Dolled-Filhart, M.; Gandhi, L. |
| Abstract Title: | Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population |
| Meeting Title: | 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 50 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2014 Nov 18-21 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2014-11-01 |
| Start Page: | 44 |
| End Page: | 45 |
| Language: | English |
| ACCESSION: | WOS:000347755700128 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(14)70253-9 |
| Notes: | Meeting Abstract: 127 -- 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics -- NOV 18-21, 2014 -- Barcelona, SPAIN -- Source: Wos |
